{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Chang A"],"funding":["the Winship Cancer Institute at Emory University Neil W. and William S. Elkin Fellowship to A. Chang","NCI NIH HHS"],"pagination":["55-70"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5762391"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["27(1)"],"pubmed_abstract":["<h4>Introduction</h4>Inhibitors against the PD-1/PD-L1 pathway are revolutionizing the treatment and management of malignancies.<h4>Areas covered</h4>We summarize our current understanding of the function of PD-1, its role in immune evasion, the clinical data available that support the use of PD-1 antagonist in Hodgkin and non-Hodgkin lymphomas, and potential predictors of response.<h4>Expert opinion</h4>We anticipate that in the next 10 years, agents that modulate the immune system such as PD-1 antagonists will be increasingly used in favor over traditional cytotoxic chemotherapeutic agents. PD-1 antagonists will be combined with future immunotherapies or used as adjuncts to cellular therapy to boost tumor-specific immune responses."],"journal":["Expert opinion on investigational drugs"],"pubmed_title":["Investigational PD-1 inhibitors in HL and NHL and biomarkers for predictors of response and outcome."],"pmcid":["PMC5762391"],"funding_grant_id":["4T32CA160040-04","T32 CA160040"],"pubmed_authors":["Allen PB","Chang A","Flowers CR","Schlafer D"],"additional_accession":[]},"is_claimable":false,"name":"Investigational PD-1 inhibitors in HL and NHL and biomarkers for predictors of response and outcome.","description":"<h4>Introduction</h4>Inhibitors against the PD-1/PD-L1 pathway are revolutionizing the treatment and management of malignancies.<h4>Areas covered</h4>We summarize our current understanding of the function of PD-1, its role in immune evasion, the clinical data available that support the use of PD-1 antagonist in Hodgkin and non-Hodgkin lymphomas, and potential predictors of response.<h4>Expert opinion</h4>We anticipate that in the next 10 years, agents that modulate the immune system such as PD-1 antagonists will be increasingly used in favor over traditional cytotoxic chemotherapeutic agents. PD-1 antagonists will be combined with future immunotherapies or used as adjuncts to cellular therapy to boost tumor-specific immune responses.","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Jan","modification":"2025-04-19T13:06:55.339Z","creation":"2019-03-26T22:28:31Z"},"accession":"S-EPMC5762391","cross_references":{"pubmed":["29228840"],"doi":["10.1080/13543784.2018.1416091"]}}